Scinovex
reviewTop 1% cited

Screening for breast cancer with mammography

Cochrane Database of Systematic Reviews · 2013 · Vol. 2013(6) · pp. CD001877–CD001877
Peter C GøtzscheKarsten Juhl Jørgensen

Abstract

If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and overtreatment is at 30%, it means that for every 2000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings. To help ensure that the women are fully informed before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk. Because of substantial advances in treatment and greater breast cancer awareness since the trials were carried out, it is likely that the absolute effect of screening today is smaller than in the trials. Recent observational studies show more overdiagnosis than in the trials and very little or no reduction in the incidence of advanced cancers with screening.

Global Cancer Incidence and ScreeningCancer Risks and FactorsBRCA gene mutations in cancerMedicineBreast cancerRelative riskMammographyConfidence intervalCancerClinical trialBreast cancer screeningGynecologyInternal medicine

MeSH terms

AdultAgedBreast NeoplasmsCause of DeathDiagnostic ErrorsFemaleHumansMammographyMass ScreeningMastectomyMiddle AgedPamphletsPatient Education as TopicRandomized Controlled Trials as Topic
Citations
1,870
FWCI
92.88
field-weighted impact
References
428
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.